Literature DB >> 20653717

Volume overload and cardiorenal syndromes.

Claudio Ronco1, Alan Maisel.   

Abstract

To include the vast array of interrelated derangements and to stress the bidirectional nature of the heart-kidney interactions, the classification of the cardiorenal syndrome today includes 5 subtypes whose terminology reflects their primary and secondary pathology, time frame, and the presence of concomitant cardiac and renal dysfunction. Cardiorenal syndromes (CRSs) are pathophysiologic disorders of the heart and kidneys whereby acute or chronic dysfunction of one organ may induce acute or chronic dysfunction of the other. Type 1 CRS reflects an abrupt worsening of cardiac function leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function causing progressive chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function causing acute cardiac disorder. Type 4 CRS describes a state of chronic kidney disease contributing to decreased cardiac function, cardiac hypertrophy, and/or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (eg, sepsis) simultaneously causing both cardiac and renal dysfunction. Biomarkers can help characterize the subtypes of CRS as well as suggest the timing of treatment initiation and its likely effectiveness. The identification of patients and the pathophysiologic mechanisms underlying each syndrome subtype, including fluid overload or, in general, altered conditions of fluid status, can help physicians understand clinical derangements, provide the rationale for management strategies, and allow the design of future clinical trials with more accurate selection and stratification of the population under investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653717     DOI: 10.1111/j.1751-7133.2010.00176.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  8 in total

1.  Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement.

Authors:  Katherine B Pronschinske; Sylvia Qiu; Christina Wu; Tomoko S Kato; Tuba Khawaja; Hiroo Takayama; Yoshifumi Naka; Danielle L Templeton; Isaac George; Maryjane A Farr; Donna M Mancini; P Christian Schulze
Journal:  J Heart Lung Transplant       Date:  2014-06-23       Impact factor: 10.247

2.  Diastolic dysfunction and contrast-induced nephropathy in patients undergoing coronary angiography.

Authors:  S Acikel; R Akdemir; H Kilic; G Cagirci; M Dogan; A B Yesilay; E Yeter
Journal:  Herz       Date:  2014-11-30       Impact factor: 1.443

3.  Predictors of outpatient kidney function recovery among patients who initiate hemodialysis in the hospital.

Authors:  LaTonya J Hickson; Sanjay Chaudhary; Amy W Williams; John J Dillon; Suzanne M Norby; James R Gregoire; Robert C Albright; James T McCarthy; Bjorg Thorsteinsdottir; Andrew D Rule
Journal:  Am J Kidney Dis       Date:  2014-11-05       Impact factor: 8.860

4.  Fluid overload and changes in serum creatinine after cardiac surgery: predictors of mortality and longer intensive care stay. A prospective cohort study.

Authors:  Anna Stein; Lucas Vieira de Souza; Cassian Rodrigues Belettini; Willian Roberto Menegazzo; Júlio Rosales Viégas; Edemar Manuel Costa Pereira; Renato Eick; Lilian Araújo; Fernanda Consolim-Colombo; Maria Cláudia Irigoyen
Journal:  Crit Care       Date:  2012-05-31       Impact factor: 9.097

5.  Preliminary Investigation of Cardiovascular-Renal Disorders in Dogs with Chronic Mitral Valve Disease.

Authors:  E Martinelli; C Locatelli; S Bassis; S Crosara; S Paltrinieri; P Scarpa; I Spalla; A M Zanaboni; C Quintavalla; P Brambilla
Journal:  J Vet Intern Med       Date:  2016-09       Impact factor: 3.333

6.  Reliability of symmetric dimethylarginine in dogs with myxomatous mitral valve disease as kidney biomarker.

Authors:  Alice Savarese; Monica Probo; Chiara Locatelli; Sergio Aurelio Zanzani; Alessia Libera Gazzonis; Melissa Papa; Paola Giuseppina Brambilla
Journal:  Open Vet J       Date:  2018-08-19

7.  A Clinically Relevant Functional Model of Type-2 Cardio-Renal Syndrome with Paraventricular Changes consequent to Chronic Ischaemic Heart Failure.

Authors:  Joanne Clare Harrison; Scott Duncan George Smart; Emma Maria Hinemoa Besley; Jessica Renee Kelly; Morgayn Iona Read; Yimin Yao; Ivan Andrew Sammut
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

8.  MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4.

Authors:  Sandra Chuppa; Mingyu Liang; Pengyuan Liu; Yong Liu; Marc C Casati; Allen W Cowley; Leah Patullo; Alison J Kriegel
Journal:  Kidney Int       Date:  2017-07-29       Impact factor: 10.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.